NCT06242119 Clinical Application of the J-PET Scanner Prototype
| NCT ID | NCT06242119 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jagiellonian University |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2024-03-07 |
| Primary Completion | 2024-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2024-03-07 with a primary completion date of 2024-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Positron emission tomography (PET), an advanced diagnostic imaging technique, exploits the annihilation of positrons (e+) to delineate pathological alterations within diseased tissues. Integral to PET scanners are detector systems that transform gamma photons into fluorescent photons, thereby gleaning insights into the energy, time, and spatial distribution of gamma photons emanating from positron-emitting radiopharmaceuticals. Conventional PET scanners, bear a significant financial burden primarily due to their reliance on LSO (lutetium oxyorthosilicate) or LYSO (lutetium yttrium oxyorthosilicate) scintillation crystals. The exorbitant cost and limited availability of these crystal scintillators impede the widespread adoption of PET scanners. In a departure from conventional PET technology, the prototype J-PET scanner employed in this trial employs plastic scintillators, characterized by unique physical properties. This prototype is further equipped with bespoke software enabling three-photon imaging based on the annihilation of ortho-positronium (o-Ps) generated within diseased tissue. This study delves into the clinical applicability of PET scanners employing plastic scintillators, particularly investigating the feasibility of PET imaging using plastic scintillators where gamma quanta interact by mechanisms other than the photoelectric effect. Furthermore, this study endeavors to contemporaneously acquire and analyze data related to the lifetime of ortho-positronium (o-P) atoms emanating from routine radiopharmaceuticals. Additionally, it seeks to validate the utilization of a novel diagnostic indicator, termed the \"positron biomarker,\" through a prospective study, comparing its efficacy to conventional diagnostic PET scanning methodologies.
Eligibility Criteria
Inclusion Criteria: * The patient is referred for a PET/CT scan, in accordance with recognized indications for examining the entire body. * Age over 18 years * Informed, voluntary consent to participate in the study Exclusion Criteria: * Pregnant women, breastfeeding women * People with a previously diagnosed allergy to radiopharmaceuticals * Age under 18 years * Lack of cooperation with the patient * Lack of informed consent to participate in the study
Contact & Investigator
Marta Opalinska, MD, PhD
PRINCIPAL INVESTIGATOR
Department of Endocrinology and Nuclear Medicine, University Hospital in Krakow
Frequently Asked Questions
Who can join the NCT06242119 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06242119 currently recruiting?
Yes, NCT06242119 is actively recruiting participants. Contact the research team at p.moskal@uj.edu.pl for enrollment information.
Where is the NCT06242119 trial being conducted?
This trial is being conducted at Krakow, Poland.
Who is sponsoring the NCT06242119 clinical trial?
NCT06242119 is sponsored by Jagiellonian University. The principal investigator is Marta Opalinska, MD, PhD at Department of Endocrinology and Nuclear Medicine, University Hospital in Krakow. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.